Tags

Type your tag names separated by a space and hit enter

Osimertinib in the treatment of leptomeningeal disease in T790M-negative, epidermal growth factor receptor-mutated non-small cell lung cancer: a case report.
Chin Clin Oncol. 2019 Jun; 8(3):29.CC

Abstract

Leptomeningeal carcinomatosis (LMC) is a terminal event in advanced cancer, its incidence in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is increasing due to recent advances in systemic therapy and prolongation of survival. Osimertinib is a third generation EGFR-tyrosine kinase inhibitor (TKI) with preclinical and early clinical studies showing activity against LMC resistant to previous TKI treatments and acquired T790M mutation. We report a case of osimertinib in the treatment of LMC in a T790M-negative, EGFR-mutated NSCLC with significant clinical benefit and no toxicity. Osimertinib is a potentially effective treatment for LMC associated with EGFR-mutated NSCLC regardless of T790M status and a well-tolerated treatment for poor performance status patients.

Authors+Show Affiliations

Department of Medical Oncology, St George Hospital, Sydney, Australia; St George Clinical School, University of New South Wales, Sydney, Australia. j.chen@garvan.org.au.Department of Medical Oncology, St George Hospital, Sydney, Australia; Department of Medical Oncology, The Sutherland Hospital, Sydney, Australia.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

30943730

Citation

Chen, Julia, and Hussein Soudy. "Osimertinib in the Treatment of Leptomeningeal Disease in T790M-negative, Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer: a Case Report." Chinese Clinical Oncology, vol. 8, no. 3, 2019, p. 29.
Chen J, Soudy H. Osimertinib in the treatment of leptomeningeal disease in T790M-negative, epidermal growth factor receptor-mutated non-small cell lung cancer: a case report. Chin Clin Oncol. 2019;8(3):29.
Chen, J., & Soudy, H. (2019). Osimertinib in the treatment of leptomeningeal disease in T790M-negative, epidermal growth factor receptor-mutated non-small cell lung cancer: a case report. Chinese Clinical Oncology, 8(3), 29. https://doi.org/10.21037/cco.2019.02.02
Chen J, Soudy H. Osimertinib in the Treatment of Leptomeningeal Disease in T790M-negative, Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer: a Case Report. Chin Clin Oncol. 2019;8(3):29. PubMed PMID: 30943730.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Osimertinib in the treatment of leptomeningeal disease in T790M-negative, epidermal growth factor receptor-mutated non-small cell lung cancer: a case report. AU - Chen,Julia, AU - Soudy,Hussein, Y1 - 2019/03/04/ PY - 2018/10/01/received PY - 2019/02/14/accepted PY - 2019/4/5/pubmed PY - 2019/4/5/medline PY - 2019/4/5/entrez KW - nonsmall cell lung cancer (NSCLC) KW - Epidermal growth factor receptor (EGFR) mutation KW - T790M mutation KW - leptomeningeal carcinomatosis (LMC) KW - osimertinib SP - 29 EP - 29 JF - Chinese clinical oncology JO - Chin Clin Oncol VL - 8 IS - 3 N2 - Leptomeningeal carcinomatosis (LMC) is a terminal event in advanced cancer, its incidence in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is increasing due to recent advances in systemic therapy and prolongation of survival. Osimertinib is a third generation EGFR-tyrosine kinase inhibitor (TKI) with preclinical and early clinical studies showing activity against LMC resistant to previous TKI treatments and acquired T790M mutation. We report a case of osimertinib in the treatment of LMC in a T790M-negative, EGFR-mutated NSCLC with significant clinical benefit and no toxicity. Osimertinib is a potentially effective treatment for LMC associated with EGFR-mutated NSCLC regardless of T790M status and a well-tolerated treatment for poor performance status patients. SN - 2304-3873 UR - https://www.unboundmedicine.com/medline/citation/30943730/Osimertinib_in_the_treatment_of_leptomeningeal_disease_in_T790M_negative_epidermal_growth_factor_receptor_mutated_non_small_cell_lung_cancer:_a_case_report_ L2 - https://doi.org/10.21037/cco.2019.02.02 DB - PRIME DP - Unbound Medicine ER -